fashion -WSS

fashion

author：fashion 2025-09-06 01:58:46 - browse：5

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Global childhood vaccinations edge closer to pre

WSS

Vivek Ramaswamy made waves in the debate, much as in biotech

Intellia plays down concerns on accidental germline transmission

Congress: Eradicate hepatitis C and reduce the deficit

Trans patients at the end of life deserve respect and dignity

Can U.S. cancer drug shortages be fixed?

Intellia plays down concerns on accidental germline transmission

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Trans patients at the end of life deserve respect and dignity

What does generative AI mean for health care? We asked experts

Study: Spinal cord stimulation helps patients with paralysis walk again

State Dept. review finds Biden bears some blame for Afghanistan failures

Grail faces three suits alleging harassment, retaliation

Drug repurposing or repositioning? The language matters

Celiac disease study examines precisely how gluten triggers injury

How to save PrEP access — and even expand it

Roche's accidental data boosts hopes for anti

explore

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

People can get long Covid without testing positive for virus: Study

Blood tests recalled over risk of missed heart attack diagnosis

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Europe sees delivery challenges ahead on Alzheimer's therapies

Meadows told special counsel he could not recall Trump ever declassifying Mar

Wikipedia

focus

knowledge

hotspot